INE-963
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- INE-963
- Molecular weight
- 402.52
- Structure (SMILES)
- COc1nc(C(C)C)ccc1-c1cnc2sc(N3CCC(O)(CN)CC3)nn12
- ine 963
- INE 963
- Ine-963
- ine963
- Ine963
- INE963
- CAS registry numbers
- 2640567-43-5
- ChEMBL ID
- CHEMBL5173264
- InChIKey
- JYHSRMKXBAPFST-UHFFFAOYSA-N
- PubChem compound IDs
- 156274257
- FDA ingredient codes (UNII)
- 4HRQ96CC7C
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- INE963
- Type
- Synthetic organic
Investigated indications
- Condition
- Malaria, Falciparum
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007444
- Subject identifier
- D016778
Open Targets indications
- Condition identifier
- MONDO_0005920
- Highest recorded phase
- 2
Trial references
- NCT05750628
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 2
- Polar surface area
- 101.8
- Calculated partition coefficient (ALogP)
- 2.27
- Calculated partition coefficient (XLogP)
- 2.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 28
- Molecular formula
- C19H26N6O2S
- Monoisotopic mass
- 402.18379527
- Natural product
- No
- Recorded assays
- 115
- Active assays
- 15
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (3)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
- Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants
In development for (1)
- Plasmodium falciparum malaria Phase 2